YM 116

Drug Profile

YM 116

Alternative Names: YM116

Latest Information Update: 12 Feb 2007

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Antineoplastics
  • Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 12 Feb 2007 Discontinued - Phase-I for Prostate cancer in Japan (PO)
  • 12 Feb 2007 Discontinued - Phase-I for Prostate cancer in Netherlands (PO)
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top